Cost Effectiveness Of Warfarin Dose Genotyping To Be Assessed In Medco/Mayo Clinic Study
This article was originally published in The Pink Sheet Daily
Study will determine if the cost of testing is justified by the savings created in preventing warfarin-related bleeding events.
You may also be interested in...
The Critical Path Institute, in conjunction with the University of Utah, will be awarded $750,000 in funding by FDA to be used, in part, to validate and standardize genetic testing for biomarkers related to warfarin efficacy and metabolism.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.